Fewer than 100 children are known to have ML4. Families spent nearly a decade building its first gene therapy trial
The ML4 Foundation says the FDA has allowed the first U.S. human trial of an AAV9 gene therapy for mucolipidosis type IV to proceed, opening clinical testing for an ultra-rare neurodegenerative disease with no approved disease-modifying therapy.